Table 1 Patient characteristics
From: Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma
Systemic chemotherapy | ||||||
|---|---|---|---|---|---|---|
All patients | Yes | No | ||||
N | % | N | % | N | % | |
Age | ||||||
Median (range) | 69 (40–93) | 66 (40–80) | 75 (52–93) | |||
Sex | ||||||
Male | 237 | 86.5 | 143 | 84.6 | 94 | 89.5 |
Female | 37 | 13.5 | 26 | 15.4 | 11 | 10.5 |
Histopathology | ||||||
Epithelioid | 115 | 42.0 | 68 | 40.2 | 47 | 44.8 |
Biphasic | 36 | 13.1 | 26 | 15.4 | 10 | 9.5 |
Sarcomatous | 32 | 11.7 | 19 | 11.2 | 13 | 12.4 |
Others | 91 | 33.2 | 56 | 33.1 | 35 | 33.3 |
AJCC stage | ||||||
I–II | 137 | 50.0 | 79 | 46.7 | 58 | 55.2 |
III–IV | 119 | 43.4 | 86 | 50.9 | 33 | 31.4 |
Missing | 18 | 6.6 | 4 | 2.4 | 14 | 13.3 |
ECOG performance status | ||||||
0–1 | 234 | 85.4 | 161 | 95.3 | 73 | 69.5 |
2–3 | 32 | 11.7 | 8 | 4.7 | 24 | 22.9 |
Missing | 8 | 2.9 | 0 | 0.0 | 8 | 7.6 |
Weight loss | ||||||
Absent | 140 | 51.1 | 95 | 56.2 | 45 | 42.9 |
Present | 125 | 45.6 | 74 | 43.8 | 51 | 48.6 |
Missing | 9 | 3.3 | 0 | 0.0 | 9 | 8.6 |
Chest pain | ||||||
Absent | 98 | 35.8 | 64 | 37.9 | 34 | 32.4 |
Present | 169 | 61.7 | 105 | 62.1 | 64 | 61.0 |
Missing | 7 | 2.6 | 0 | 0.0 | 7 | 6.7 |
EORTC prognostic group | ||||||
Low risk | 135 | 49.3 | 81 | 47.9 | 54 | 51.4 |
High risk | 139 | 50.7 | 88 | 52.1 | 51 | 48.6 |
CALGB prognostic group | ||||||
1 or 2 | 56 | 20.4 | 34 | 20.1 | 22 | 21.0 |
3 or 4 | 131 | 47.8 | 92 | 54.4 | 39 | 37.1 |
5 or 6 | 80 | 29.2 | 43 | 25.4 | 37 | 35.2 |
Missing | 7 | 2.6 | 0 | 0.0 | 7 | 6.7 |
Neutrophil-to-lymphocyte ratio at baseline | ||||||
Median (range) | 3.53 (1.28–22.6) | 3.39 (1.48–13.62) | 3.77 (1.28–22.6) | |||
<5 | 202 | 73.7 | 129 | 76.3 | 73 | 69.5 |
⩾5 | 72 | 26.3 | 40 | 23.7 | 32 | 30.5 |
Overall survival from diagnosis | ||||||
Median, months (CI) | 13.3 (11.6–15.1) | 15.2 (13.8–17.9) | 8.3 (5.7–11.1) | |||
